ClinicalTrials.gg
RecruitingNCT07844941Updated Sep 28, 2026

Artificial Intelligence (AI)-Based Personalized Exercise Coaching for Patients With Breast Cancer

An interventional study of AI-Based Personalized Exercise Coaching and Conventional Exercise Guidance in Breast Cancer, sponsored by Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Breast Neoplasms by Shanghai Jiao Tong University School of Medicine — 10 open to participants now, 13 under way, 2 of them phase 3. Breast Neoplasms · Shanghai Jiao Tong University School of Medicine.

Planned enrollment
12th of 18
60 · median 106
Started
2026
with 2 others
No phase
2 of 21
1 open now
Primary completion
2027-03
later than 7 of 12 live
Registered
21st of 21
by date

Among the 21 studies in Breast Neoplasms by Shanghai Jiao Tong University School of Medicine, this one is the 12th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 21st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

10 of the 21 studies in Breast Neoplasms by Shanghai Jiao Tong University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Breast Neoplasms by Shanghai Jiao Tong University School of Medicine, or all of them as a file.
02

Study summary

This prospective, single-center, randomized controlled trial aims to evaluate the effectiveness and safety of an artificial intelligence (AI)-based personalized exercise coaching system in female breast cancer survivors who have completed major cancer treatment and are clinically stable. A total of 100 eligible participants will be randomly assigned in a 1:1 ratio to either an AI-based exercise coaching group or a conventional exercise guidance group. Participants in the intervention group will receive personalized exercise recommendations generated by the AI exercise coaching system, with exercise data collected and used for dynamic adjustment of exercise guidance. Participants in the control group will receive conventional exercise recommendations provided by healthcare professionals. The intervention will last for 6 months. Exercise adherence will be evaluated as the primary outcome. Secondary outcomes will include quality of life, psychological status, physical function, exercise-related adverse events, and laboratory and metabolic parameters.

Read the detailed description

Regular physical activity is recommended for patients with cancer and may improve physical function, psychological well-being, and quality of life. However, conventional exercise guidance may be limited by insufficient personalization, limited professional resources, and difficulties in continuously monitoring exercise behavior.

The AI-based exercise coaching system evaluated in this study is designed to provide personalized exercise recommendations and dynamically adjust exercise guidance based on individual characteristics and exercise data. The system integrates exercise-related knowledge and uses wearable devices to collect exercise data for monitoring and feedback.

This study is a prospective, single-center, open-label, randomized controlled trial conducted among female patients with breast cancer who have completed major cancer treatment and are clinically stable. One hundred eligible participants will be randomized in a 1:1 ratio to the AI-based exercise coaching group or the conventional exercise guidance group.

Participants assigned to the AI-based exercise coaching group will follow individualized exercise programs generated by the system and will upload exercise data to enable dynamic guidance and adjustment. Participants assigned to the control group will receive general exercise recommendations from healthcare professionals.

The intervention period will be 6 months. Assessments will be conducted at baseline, 3 months, and 6 months. The primary outcome will be exercise adherence. Secondary outcomes will include quality of life, psychological status, physical function, exercise-related safety outcomes, and laboratory and metabolic parameters.

03

Conditions studied

  • Breast Cancer

Keywords

  • Breast Cancer
  • Exercise
  • Artificial Intelligence
  • Digital Health
  • Physical Activity
  • Exercise Adherence
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of written and dated .
  2. Female participants aged 18 to 70 years.
  3. confirmed breast .
  4. Completion of major cancer treatment, including surgery, chemotherapy, and/or radiotherapy, with clinically stable disease.
  5. No severe cardiopulmonary dysfunction or to exercise.

Exclusion criteria

Exclusion Criteria:

  1. Have not undergone breast cancer surgery.
  2. Mental or psychological condition, as judged by the investigator, that would prevent adherence to the intervention or completion of follow-up.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    The AI-Based Exercise Coaching Group

    Participants assigned to this group will use an AI-based exercise coaching system for 6 months. The system will generate individualized exercise recommendations based on participant characteristics and health-related information. Exercise data will be collected and uploaded to the system, allowing exercise recommendations to be dynamically adjusted according to participants' exercise performance and status. Participants will also receive regular follow-up during the intervention period.

    Device: AI-Based Personalized Exercise Coaching

  • Active comparator
    The Control Group

    Participants assigned to the control group will receive conventional exercise guidance from healthcare professionals based on routine clinical practice and professional experience, including general recommendations such as approximately 150 minutes of moderate-intensity aerobic exercise per week. Participants will receive regular follow-up during the 6-month study period.

    Behavioral: Conventional Exercise Guidance

Interventions

  • DeviceAI-Based Personalized Exercise Coaching

    Participants will receive individualized exercise recommendations generated by an AI-based exercise coaching system. The system provides personalized exercise guidance and uses exercise data collected to monitor exercise performance and dynamically adjust recommendations. The intervention will be delivered for 6 months.

  • BehavioralConventional Exercise Guidance

    General exercise recommendations will be provided by healthcare professionals according to routine clinical practice.

06

What researchers measure

Primary outcomes

  1. Exercise Adherence

    Exercise adherence will be calculated as the ratio of the participant's actual exercise frequency to the recommended exercise frequency during the intervention period, expressed as a percentage. Exercise adherence will be compared between the AI-based exercise coaching group and the conventional exercise guidance group.

    Time frame: 6 months

Secondary outcomes

  1. Change in Health-Related Quality of Life

    Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores will be calculated according to the EORTC scoring procedures, with domain scores transformed to a 0-100 scale. Higher scores on functional scales and global health status indicate better functioning or quality of life, whereas higher scores on symptom scales indicate greater symptom burden.

    Time frame: Baseline, 3 months, and 6 months

  2. Change in Anxiety Symptoms

    Anxiety symptoms will be assessed using the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). The HADS-A score ranges from 0 to 21. Higher scores indicate more severe anxiety symptoms.

    Time frame: Baseline, 3 months, and 6 months

  3. Change in Depressive Symptoms

    Depressive symptoms will be assessed using the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). The HADS-D score ranges from 0 to 21. Higher scores indicate more severe depressive symptoms.

    Time frame: Baseline, 3 months, and 6 months

  4. Change in Peak Oxygen Uptake

    Peak oxygen uptake (VO₂peak) will be measured by cardiopulmonary exercise testing (CPET) on an electronically braked cycle ergometer, using a CORTEX MetaLyzer 3B-R3 metabolic cart, during a symptom-limited incremental exercise protocol. VO₂peak is recorded at the highest oxygen uptake achieved during the test. The unit of measurement is mL/kg/min.

    Time frame: Baseline, 3 months, and 6 months

  5. Change in Muscle Strength

    Muscle strength of upper- and lower-extremity groups will be assessed bilaterally by manual muscle testing (MMT) using the Medical Research Council (MRC) 0-5 grading scale. The unit of measurement is MRC muscle grade (0-5). Higher grades indicate greater muscle strength.

    Time frame: Baseline, 3 months, and 6 months

  6. Change in Joint Range of Motion

    Active and passive joint range of motion (AROM and PROM) of the shoulder, elbow and wrist will be measured using a universal goniometer, on both left and right sides. The unit of measurement is degrees (°).

    Time frame: Baseline, 3 months, and 6 months

  7. Change in Low-Density Lipoprotein Cholesterol (LDL-C)

    Low-density lipoprotein cholesterol will be measured from fasting venous blood samples using an automatic biochemical analyzer. The unit of measurement is mmol/L.

    Time frame: Baseline, 3 months, and 6 months

  8. Change in Total Cholesterol

    Total cholesterol will be measured from fasting venous blood samples using an automatic biochemical analyzer. The unit of measurement is mmol/L.

    Time frame: Baseline, 3 months, and 6 months

  9. Change in Fasting C-Peptide

    Fasting C-peptide will be measured from venous blood samples collected after at least 8 hours of overnight fasting, using a chemiluminescent immunoassay analyzer. The unit of measurement is ng/mL.

    Time frame: Baseline, 3 months, and 6 months

  10. Incidence of Exercise-Related Adverse Events

    The number and proportion (%) of participants experiencing exercise-related adverse events, including muscle strain, joint sprain, falls, and other exercise-related injuries, will be recorded during the intervention period. The outcome is reported as the percentage of participants with at least one exercise-related adverse event. The unit of measurement is percentage (%).

    Time frame: From baseline through 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — De-identified individual participant data collected in this study will not be shared with external researchers, as the data contain sensitive health information from breast cancer survivors and are intended solely for the primary research group's analyses.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Mar 2027, 8 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 8 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2026
First posted
Sep 28, 2026
StartActual
Jul 22, 2026
Primary completionEst.
Mar 22, 2027
CompletionEst.
Mar 22, 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07844941
Responsible party
Kunwei Shen (Professor, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Sep 28, 2026
Start date
Jul 22, 2026
Primary completion
Mar 22, 2027 (estimated)
Completion
Mar 22, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Siji Zhu, MD
Contact
zsj_mu@yeah.net
021-64370045
Xiaosong Chen, Professor
Contact
chenxiaosong0156@hotmail.com
021-64370045

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion